Dyslipidemia Pipeline 2025: FDA Approvals, Therapies, Clinical Trials, and Latest Developments Unveiled by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Dyslipidemia pipeline constitutes key companies continuously working towards developing Dyslipidemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Dyslipidemia Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Dyslipidemia Market.

The Dyslipidemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Dyslipidemia Pipeline Report: https://www.delveinsight.com/sample-request/dyslipidemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Dyslipidemia treatment therapies with a considerable amount of success over the years.
• Dyslipidemia companies working in the treatment market areMerck Group, Pfizer, Sanofi, Alnylam Pharmaceuticals, Amarin Corporation, Amgen, Bristol Myers Squibb, Cipla, CKD Bio Corporation, AstraZeneca, Daewoong Pharmaceutical, Daiichi Sankyo, Inc, Eli Lilly and Company, Esperion, GSK, Jw Pharmaceuticals Limited, Kadmon, a Sanofi Company, Lupin Pharmaceuticals, and others, are developing therapies for the Dyslipidemia treatment
• Emerging Dyslipidemia therapies in the different phases of clinical trials are- Pemafibrate (K-877), AZD8233, Rosuvastatin, GW856553, A3309, TA-8995, Alirocumab, Muraglitazar, Atorvastatin (Lipilou), MK1903, Lapaquistat acetate, PPAR alpha, and others are expected to have a significant impact on the Dyslipidemia market in the coming years.
• In April 2025, In the PROLONG-ANG3 trial, Eli Lilly's solbinsiran, an N-acetylgalactosamine-conjugated small interfering RNA, demonstrated reductions in apolipoprotein B among patients with mixed dyslipidemia. Similarly, in a Phase 2 study, SHR-1918, a monoclonal antibody developed by Jiangsu Hengrui Pharmaceuticals, showed decreases in LDL, triglycerides, and other lipid levels in patients with inadequately managed hyperlipidemia.
• In November 2024, NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage clinical biopharmaceutical firm developing oral, non-statin medications for patients at risk of cardiovascular disease (CVD) with elevated low-density lipoprotein cholesterol (LDL-C), who do not respond well to existing therapies, today announced positive topline results from its Phase 3 TANDEM clinical trial (NCT06005597). The TANDEM trial will support global regulatory submissions for the 10 mg obicetrapib and 10 mg ezetimibe fixed-dose combination in adult patients with heterozygous familial hypercholesterolemia (HeFH) and/or atherosclerotic cardiovascular disease (ASCVD) or multiple ASCVD risk factors, whose LDL-C remains inadequately controlled despite receiving maximally tolerated lipid-lowering therapy.
• In August 2024, At the European Society of Cardiology (ESC) 2024 meeting, Dr. Erin Michos discussed the success of obicetrapib trials thus far. NewAmsterdam has demonstrated promising results in all Phase II trials, including ROSE2, TULIP, ROSE, and OCEAN, which assessed obicetrapib as both a monotherapy and combination therapy, showing its ability to significantly lower low-density lipoprotein (LDL) levels. The completion of patient enrollment in the Phase III TANDEM trial marks a key milestone towards the potential launch of obicetrapib, bringing NewAmsterdam closer to offering a new treatment option for dyslipidemia, heterozygous familial hypercholesterolemia (HeFH), and/or atherosclerotic cardiovascular disease (ASCVD).
• In July 2024, NewAmsterdam Pharma reported positive results from the first of its four pivotal Phase III trials, demonstrating that its lead cardiovascular candidate, obicetrapib, effectively lowers cholesterol levels. The BROOKLYN trial (NCT05425745) is the initial study in NewAmsterdam's portfolio, focused on assessing obicetrapib in adult patients with heterozygous familial hypercholesterolemia (HeFH) whose LDL-C remains inadequately managed despite receiving the maximum tolerated lipid-lowering therapy.

Dyslipidemia Overview
Dyslipidemia is a medical condition characterized by abnormal levels of lipids (fats) in the blood. These lipids include cholesterol and triglycerides, which are essential for various body functions but can pose health risks when imbalanced.

Get a Free Sample PDF Report to know more about Dyslipidemia Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/dyslipidemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Dyslipidemia Drugs Under Different Phases of Clinical Development Include:
• Pemafibrate (K-877): Kowa Company
• AZD8233: AstraZeneca And Parexel
• Rosuvastatin: AstraZeneca
• GW856553: GlaxoSmithKline
• A3309: Albireo
• TA-8995: Xention Ltd
• Alirocumab: Sanofi
• Muraglitazar: Bristol-Myers Squibb
• Atorvastatin (Lipilou): Chong Kun Dang Pharmaceutical
• MK1903: Merck Sharp & Dohme LLC
• Lapaquistat acetate: Takeda
• PPAR alpha: Eli Lilly and Company

Dyslipidemia Pipeline Therapeutics Assessment
• Dyslipidemia Assessment by Product Type
• Dyslipidemia By Stage and Product Type
• Dyslipidemia Assessment by Route of Administration
• Dyslipidemia By Stage and Route of Administration
• Dyslipidemia Assessment by Molecule Type
• Dyslipidemia by Stage and Molecule Type

DelveInsight's Dyslipidemia Report covers around products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Dyslipidemia product details are provided in the report. Download the Dyslipidemia pipeline report to learn more about the emerging Dyslipidemia therapies at:
https://www.delveinsight.com/sample-request/dyslipidemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Dyslipidemia Therapeutics Market include:
Key companies developing therapies for Dyslipidemia are - DAEWOONG BIO, DAIICHI SANKYO COMPANY, LIMITED, Eli Lilly and Company, ESPERION Therapeutics, Inc., GlaxoSmithKline plc, JW Pharmaceutical, AstraZeneca, Merck & Co., Inc., Pfizer Inc., Sanofi, Alnylam Pharmaceuticals, Inc., AMARIN CORPORATION, Amgen Inc., Bristol-Myers Squibb Company, Mylan N.V., Catabasis Pharmaceuticals, Cipla Inc., Lupin Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd, Novartis, Bayer AG, and others.

Dyslipidemia Pipeline Analysis:
The Dyslipidemia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Dyslipidemia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dyslipidemia Treatment.
• Dyslipidemia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Dyslipidemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dyslipidemia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Dyslipidemia drugs and therapies-
https://www.delveinsight.com/sample-request/dyslipidemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Dyslipidemia Pipeline Market Drivers
• Increasing global geriatric population, Increase in the prevalence of lifestyle related and cardiovascular disorders, are some of the important factors that are fueling the Dyslipidemia Market.

Dyslipidemia Pipeline Market Barriers
• However, Significant proportion of treated patients do not reach recommended treatment goal, Increase in availability of generic drugs, and other factors are creating obstacles in the Dyslipidemia Market growth.

Scope of Dyslipidemia Pipeline Drug Insight
• Coverage: Global
• Key Dyslipidemia Companies: Merck Group, Pfizer, Sanofi, Alnylam Pharmaceuticals, Amarin Corporation, Amgen, Bristol Myers Squibb, Cipla, CKD Bio Corporation, AstraZeneca, Daewoong Pharmaceutical, Daiichi Sankyo, Inc, Eli Lilly and Company, Esperion, GSK, Jw Pharmaceuticals Limited, Kadmon, a Sanofi Company, Lupin Pharmaceuticals, and others
• Key Dyslipidemia Therapies: Pemafibrate (K-877), AZD8233, Rosuvastatin, GW856553, A3309, TA-8995, Alirocumab, Muraglitazar, Atorvastatin (Lipilou), MK1903, Lapaquistat acetate, PPAR alpha, and others
• Dyslipidemia Therapeutic Assessment: Dyslipidemia current marketed and Dyslipidemia emerging therapies
• Dyslipidemia Market Dynamics: Dyslipidemia market drivers and Dyslipidemia market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.